(Q33374794)

English

Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

George Fountzilas

8

object named as

George Fountzilas

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Paris A Kosmidis

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Meletios-Athanasios Dimopoulos

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Konstantinos Syrigos

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Costas Nicolaides

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Gerasimos Aravantinos

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ioannis Boukovinas

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Dimitrios Pectasides

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Dimitrios Bafaloukos

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Charalampos Bacoyiannis

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Haralampos P Kalofonos

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

George Fountzilas

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

135-140

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES)

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930041-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1556-0864(15)30041-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410029%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33374794&oldid=1615328962"